Wang D-W, Wang Y-Q, Shu H-S
Department of Neurosurgery, the Second Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, People's Republic of China.
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9236. doi: 10.26355/eurrev_202009_22992.
Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, "MiR-16 inhibits pituitary adenoma cell proliferation via the suppression of ERK/MAPK signal pathway, by D.-W. Wang, Y.-Q. Wang, H.-S. Shu, published in Eur Rev Med Pharmacol Sci 2018; 22 (5): 1241-1248-DOI: 10.26355/eurrev_201803_14464-PMID: 29565480" has been withdrawn. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/14464.
由于本文被怀疑存在研究不当行为,且通讯作者未回应我们关于证明数据和图表原创性的要求,“D.-W. Wang、Y.-Q. Wang、H.-S. Shu发表于《欧洲医学与药理学评论》2018年;22(5):1241 - 1248 - DOI: 10.26355/eurrev_201803_14464 - PMID: 29565480的‘MiR - 16通过抑制ERK/MAPK信号通路抑制垂体腺瘤细胞增殖’”已被撤回。出版方对由此可能造成的不便表示歉意。https://www.europeanreview.org/article/14464